Transfusion最新文献

{"title":"Human leukocyte antigen alloimmunization in a randomized trial of amustaline/glutathione pathogen-reduced red cells in complex cardiac surgery patients.","authors":"Philip J Norris, Mars Stone, Clara Di Germanio, Brendan Balasko, Zhanna Kaidarova, Henry Friend, Jeanne Varrone, Laurence Corash, Nina Mufti, Richard J Benjamin","doi":"10.1111/trf.18131","DOIUrl":"https://doi.org/10.1111/trf.18131","url":null,"abstract":"<p><strong>Background: </strong>Although alloimmunization risk of pathogen-reduced (PR) platelets has been studied, the risk has not been reported with PR red blood cells (RBCs).</p><p><strong>Study design and methods: </strong>In a Phase III, randomized, controlled trial (Red Cell Pathogen Inactivation), cardiac or thoracic-aorta surgery patients were randomized to transfusion with amustaline/glutathione PR versus conventional RBCs. Pre-transfusion and Day 28 samples were evaluated for Human leukocyte antigen (HLA) Class I and Class II antibodies at low, medium, and high cutoff values.</p><p><strong>Results: </strong>The HLA alloimmunization analysis included 114 participants (53% female) in the PR and 113 (51% female) in the conventional RBC arms. In a modified intention-to-treat analysis, 13.7% (N = 29) and 7.2% (N = 15) developed new high-level HLA Class I or Class II antibodies, respectively; however, there was no signal that PR-RBCs affected the rate of HLA Class I (odds ratio (OR) 1.3 [95% confidence interval (CI) 0.62-2.9]) or Class II antibody formation (OR 0.99 [95% CI 0.35-2.8]). Female transfusion recipients had higher risk of developing new high-level HLA Class I antibodies (OR 12.0 [95% CI 3.5-40.9]) and Class II antibodies (OR 5.0 [95% CI 1.4-17]). The mean number of RBC (5.5 vs. 3.6 units, p = 0.018) and platelet (1.8 vs. 1.1 units, p = 0.043) transfusions was higher in subjects with new high-level HLA Class II antibodies.</p><p><strong>Discussion: </strong>Receipt of amustaline/glutathione PR-RBC units did not affect HLA alloimmunization risk. Female sex and number of RBC and platelet transfusions were risk factors for the development of new high-level HLA Class I and Class II antibodies.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ABO incompatibility and component irradiation are independently associated with platelet transfusion reaction rate.","authors":"Keenan O Hogan, Geethanjalee Mudunkotuwa, Milind Phadnis, X Long Zheng, Zhan Ye","doi":"10.1111/trf.18130","DOIUrl":"https://doi.org/10.1111/trf.18130","url":null,"abstract":"<p><strong>Background: </strong>Allocating incompatible platelet components to avoid product wastage must be balanced against the risk of reduced efficacy and adverse outcomes. The impact of platelet compatibility in association with product irradiation or pathogen reduction is unknown. This study aims to determine the combined and independent impact of platelet compatibility and component modification on transfusion reaction rate.</p><p><strong>Study design and methods: </strong>A retrospective review of all adult platelet transfusions from 2020 to 2022 was performed, including all reported reactions. Logistic regression was performed to evaluate the significance of ABO compatibility and unit modification for reaction rate.</p><p><strong>Results: </strong>Out of 21,330 transfusions to 3450 patients, 285 (1.33%) reactions were reported and 178 (0.83%) were diagnosed as related to transfusion, predominantly febrile nonhemolytic (n = 59) and allergic (n = 102). The compatibility of transfusion was 67.7% ABO identical, 13.8% ABO minor incompatible, 17.2% ABO major incompatible, and 1.4% ABO bidirectionally incompatible. Irradiated, unmodified, and pathogen-reduced single-donor platelets were transfused in 70.9%, 21.8%, and 7.3% of cases, respectively. Univariable regression demonstrated increased odds of reaction for major incompatibility vs. ABO identical (OR: 1.92; 95% CI: 1.36-2.71) and irradiated vs. unmodified (OR: 2.34; 95% CI: 1.45-3.91), which were confirmed by multivariable analysis. The effect of compatibility and unit modification were independent in all analyses.</p><p><strong>Conclusions: </strong>The results demonstrate a trend of increasing reaction rate associated with major incompatibility and product irradiation. This study provides additional data to inform institutional policies guiding product selection for individual patients.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Freeze-dried plasma: Hemostasis and biophysical analyses for damage control resuscitation.","authors":"Aron A Shoara, Kanwal Singh, Henry T Peng, Katy Moes, Jeong-Ah Yoo, Sahar Sohrabipour, Sanewal Singh, Rex Huang, Peter Andrisani, Chengliang Wu, Katerina Pavenski, Paul Y Kim, Bernardo Trigatti, Colin A Kretz, Ori D Rotstein, Shawn G Rhind, Andrew N Beckett","doi":"10.1111/trf.18124","DOIUrl":"https://doi.org/10.1111/trf.18124","url":null,"abstract":"<p><strong>Background: </strong>Effective hemorrhage protocols prioritize immediate hemostatic resuscitation to manage hemorrhagic shock. Prehospital resuscitation using blood products, such as whole blood or alternatively dried plasma in its absence, has the potential to improve outcomes in hemorrhagic shock patients. However, integrating blood products into prehospital care poses substantial logistical challenges due to issues with storage, transport, and administration in field environments.</p><p><strong>Study design and methods: </strong>We utilized hemostatic assays and advanced biophysical techniques, such as calorimetry, infrared spectoscopy, dynamic light scattering, and biolayer interferometry, to compare the functional and structural properties of freeze-dried plasma (FDP; OctaplasLG Powder, Octapharma AB) with those of fresh plasma controls.</p><p><strong>Results: </strong>Hemostatic characterization of FDP revealed that clot formation properties and coagulation parameters were largely comparable to fresh plasma controls, with some variations observed in Von Willebrand factor-ADAMTS13 axis and fibrinolysis. No change to moisture content of FDP (~1% water content) was observed after 6-month storage at ambient conditions. Biophysical analyses of FDP during transfusion demonstrated spontaneous exothermic mixing of FDP in plasma, a dilution effect from saline, as well as comparable stability to plasma controls. Quantification of ligand-binding affinities of platelet receptors activated GPIIbIIIa and GPIbα showed comparable binding properties to plasma controls.</p><p><strong>Conclusion: </strong>Our results show that FDP exhibits hemostatic functionality and protein stability on par with fresh plasma, as assessed by novel, highly sensitive techniques. FDP therefore represents a viable alternative to conventional plasma in damage control resuscitation, offering significant logistical and storage advantages for prehospital and remote applications, especially in scenarios where whole blood is unavailable.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Solid-phase red cell adherence versus gel column agglutination: Is there any difference for the detection of alloantibodies associated with the JK system?","authors":"Roberto Cupaiolo, Bhavna Mahadeb, Isabelle Barreau, Hanane El Kenz","doi":"10.1111/trf.18125","DOIUrl":"https://doi.org/10.1111/trf.18125","url":null,"abstract":"<p><strong>Background: </strong>Detection of alloantibodies associated with the JK system may be tricky. They are nevertheless associated with transfusion reactions and their detection is crucial.</p><p><strong>Study design and methods: </strong>Retrospectively and over a period of 7 years, we compared the results obtained using two different assays for antibody detection. We performed antibody detection testing with solid-phase red cell adherence (SPRCA). If positive, the antibody identification was carried out with the SPRCA and confirmed with the gel method in Coombs medium. In case of discrepant results occurring in recently transfused patients, we investigated these patients during the post-transfusion period.</p><p><strong>Results: </strong>Fifty-five patients with anti-JK1 or anti-JK2 were identified out of which 41 were further analyzed. Both techniques clearly identified 10 alloantibodies. In 22 cases, the alloantibody identified by SPRCA was not observed with the gel method because of negative detection tests. In one case, none of the techniques identified the alloantibody and in 8 cases, the final result was inconclusive (1/41 with the SPRCA and 8/41 with the gel method). Two patients having a highly probable delayed hemolytic transfusion reaction (DHTR) were identified among the discrepant results. For both cases, anti-JK2 was clearly identified by the SPRCA but showed inconclusive reactions with the gel method.</p><p><strong>Discussion: </strong>This study shows that in 29 out of 41 cases, the anti-JK1 or anti-JK2 identified with the SPRCA method were not with the gel method in Coombs medium. Eleven cases (11/29) were clinically significant and among them, 4 likely DHTRs and 2 highly probable DHTRs occurred.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142955554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"Universal nucleic acid donor screening revealed epidemiological features of hepatitis E and prevented transfusion-transmitted infection in Japan\".","authors":"","doi":"10.1111/trf.18076","DOIUrl":"https://doi.org/10.1111/trf.18076","url":null,"abstract":"","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142955666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of massive transfusion recipients administered ABO-incompatible fresh frozen plasma.","authors":"Joanna Bao-Ern Loh, Cameron Wellard, Helen E Haysom, Rosemary L Sparrow, Erica M Wood, Zoe K McQuilten","doi":"10.1111/trf.18070","DOIUrl":"10.1111/trf.18070","url":null,"abstract":"<p><strong>Background: </strong>The provision of ABO-incompatible fresh frozen plasma (FFP) in massive transfusion (MT) has become accepted to conserve AB FFP stock. There is an evidence gap in non-trauma settings. We compare characteristics of patients who received ABO-compatible or ABO-incompatible FFP during an MT episode due to any cause of critical bleeding, and assess the impact of incompatible FFP transfusion on inhospital mortality.</p><p><strong>Methods: </strong>Using the Australian and New Zealand Massive Transfusion Registry, data were extracted for patients aged ≥18 years who received an MT (defined as ≥5 red cell units in 4 h) between April 2011 and October 2018. Incompatible FFP was defined as transfusion of ≥1 unit of FFP with a bidirectional or minor ABO-mismatch in the first 24 h from MT initiation.</p><p><strong>Results: </strong>A total of 7340 patients from 28 hospitals were included. Seventy-seven (1%) patients received incompatible FFP (26 trauma, 51 non-trauma). Those who had incompatible FFP received a median of seven units of FFP, compared to those who only received compatible FFP receiving five units, p = .005. A total of 226 units of incompatible FFP were provided overall. Incompatible FFP provision was not independently associated with inhospital mortality in MT (HR of 1.40 [95% CI 0.84-2.26, p = .2]). Variables independently associated with inhospital mortality included increased FFP volume in the first 24 h, age, Charlson Comorbidity Index score, and lower pre-transfusion fibrinogen and peri-transfusion pH values.</p><p><strong>Conclusion: </strong>Transfusion of incompatible FFP in MT in our cohort was not independently associated with higher inhospital mortality, although the number of patients who received incompatible FFP was small.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":"58-72"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142910907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma transfusion in the intensive care unit.","authors":"Maite M T van Haeren, Senta Jorinde Raasveld, Sanne de Bruin, Merijn C Reuland, Claudia van den Oord, Jimmy Schenk, Cécile Aubron, Jan Bakker, Maurizio Cecconi, Aarne Feldheiser, Harm-Jan de Grooth, Jens Meier, Thomas W L Scheeren, Zoe McQuilten, Andrew Flint, Tarikul Hamid, Michaël Piagnerelli, Tina Tomić Mahečić, Jan Benes, Lene Russell, Hernan Aguirre-Bermeo, Konstantina Triantafyllopoulou, Vasiliki Chantziara, Mohan Gurjar, Sheila Nainan Myatra, Vincenzo Pota, Muhammed Elhadi, Ryszard Gawda, Mafalda Mourisco, Marcus Lance, Vojislava Neskovic, Matej Podbregar, Juan V Llau, Manual Quintana-Diaz, Maria Cronhjort, Carmen A Pfortmueller, Nihan Yapici, Nathan D Nielsen, Akshay Shah, Alexander P J Vlaar, Marcella C A Müller","doi":"10.1111/trf.18071","DOIUrl":"10.1111/trf.18071","url":null,"abstract":"<p><strong>Background: </strong>Current guidelines discourage prophylactic plasma use in non-bleeding patients. This study assesses global plasma transfusion practices in the intensive care unit (ICU) and their alignment with current guidelines.</p><p><strong>Study design and methods: </strong>This was a sub-study of an international, prospective, observational cohort. Primary outcomes were in-ICU occurrence rate of plasma transfusion, proportion of plasma events of total blood products events, and number of plasma units per event. Secondary outcomes included transfusion indications, INR/PT, and proportion of events for non-bleeding indications.</p><p><strong>Results: </strong>Of 3643 patients included, 356 patients (10%) experienced 547 plasma transfusion events, accounting for 18% of total transfusion events. A median of 2 (IQR 1, 2) units was given per event excluding massive transfusion protocol (MTP) and 3 (IQR 2, 6) when MTP was activated. MTP accounted for 39 (7%) of events. Indications of non-MTP events included active bleeding (54%), prophylactic (25%), and pre-procedure (12%). Target INR/PT was stated for 43% of transfusion events; pre-transfusion INR/PT or visco-elastic hemostatic assays (VHA) were reported for 73%. Thirty-seven percent of events were administered for non-bleeding indications, 54% with a pre-transfusion INR < 3.0 and 30% with an INR < 1.5.</p><p><strong>Discussion: </strong>Plasma transfusions occurred in 10% of ICU patients. Over a third were given for non-bleeding indications and might have been avoidable. Target INR/PT was not stated in more than half of transfusions, and pre-transfusion INR/PT or VHA was not reported for 27%. Further research and education is needed to optimize guideline implementation and to identify appropriate indications for plasma transfusion.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":"73-87"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11747124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric blood transfusions in Colombia: Dissecting adverse reaction trends and age dynamics.","authors":"María-Isabel Bermúdez-Forero, Diego-Alexander Anzola-Samudio, Michel-Andrés García-Otálora","doi":"10.1111/trf.18074","DOIUrl":"10.1111/trf.18074","url":null,"abstract":"<p><strong>Background: </strong>Adverse transfusion reactions (ATRs) represent undesired responses in patients. Different reports indicate that rates of ATRs are 1.3-2.6 times higher in pediatric populations compared with adults. The aim of this study was to investigate whether similar trends are observed within the pediatric population in Colombia.</p><p><strong>Study design and methods: </strong>This retrospective study, conducted from January 1, 2018, to December 31, 2022, investigated transfusion occurrences and ATRs. Data were collected from the National Hemovigilance Information System. ATRs were reported by medical personnel using standardized forms following guidelines set by the International Society of Blood Transfusion.</p><p><strong>Results: </strong>The study included 2,097,179 patients receiving 6,637,363 transfusions, with 6830 ATRs. In comparison with adult transfusions, pediatric transfusions exhibit a male bias, a higher rate of ATRs per 10,000 transfused patients (79.4 vs. 27.7), a greater prevalence of allergic reactions and a lower incidence of febrile nonhemolytic transfusion reactions (FNHTRs). The rate of ATRs varied across age groups: 17.1 for those aged 0-1 year, 120.5 for individuals aged 2-14 years, 42.5 for people aged 15-65 years, and 24.4 for those over 65 years. Among pediatric patients, 688 of 1126 allergic reactions were linked to platelet transfusions. Platelets obtained via apheresis had a higher ATR rate compared with those from the buffy coat method (OR: 1.44), while in adults, 960 of 3002 allergic reactions were attributed to platelet transfusions, with higher ATR rates for apheresis platelets compared with buffy coat platelets (OR: 1.41).</p><p><strong>Conclusion: </strong>ATRs in the Colombian pediatric population were three times higher than adults.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":"100-109"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of molecular sterility assay for rapid quality release of cord blood erythrocytes units for transfusion.","authors":"Laia Closa, Dinara Samarkanova, Carina Lera, Noemí Gonzalez, Mireia Lloret, Margarita Codinach, Gemma Aran, Jesús Fernandez-Sojo, Francisco Vidal, Maria Gloria Soria, Sergi Querol","doi":"10.1111/trf.18084","DOIUrl":"10.1111/trf.18084","url":null,"abstract":"<p><strong>Background: </strong>Umbilical cord blood (CB) units stored in banks are an important source of hematopoietic stem cells for transplantation and other cell therapies. New applications, such as their use in transfusions, require rapid quality release as cord blood red blood cells (CB-RBC) have a shorter shelf life.</p><p><strong>Study design and methods: </strong>This project aims to investigate the most prevalent microbial contaminants in CB preparations and validate a rapid sterility testing strategy for CB-RBC based on an automated system (BACT/ALERT®) in tandem with a molecular assay (real-time PCR) capable of detecting at least 100 CFU/mL of Cutibacterium acnes in CB-RBC to accelerate the detection of the most common slow-growing bacteria.</p><p><strong>Results: </strong>Microbial contamination incidence was assessed by reviewing 4696 CB sterility tests, revealing a positivity rate of 3.4%, with C. acnes being the most common slow-growing pathogen. The BACT/ALERT® system, which was validated according to European Pharmacopeia guidelines, was an appropriate method for sterility testing of CB-RBC, although it required up to 14 days of culture to detect C. acnes when iFAPlus and iFNPlus bottles were used to neutralize antimicrobials. Interestingly, the BACT/ALERT® method detected C. acnes at 30 CFU/mL within 14 days, while real-time PCR identified concentrations ≥65 CFU/mL by Day 4.</p><p><strong>Discussion: </strong>In conclusion, we developed a rapid sterility testing strategy that combines automated culture systems and real-time PCR for early microbial contamination, enhancing CB-RBC shelf life for transfusion and emphasizing the importance of combining detection methods.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":"140-151"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142795220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From pandemic to participation: A two-year follow-up of blood donors in the Netherlands who registered during the first wave of the COVID-19 pandemic.","authors":"Femmeke J Prinsze, Eva-Maria Merz, Marloes L C Spekman","doi":"10.1111/trf.18079","DOIUrl":"10.1111/trf.18079","url":null,"abstract":"<p><strong>Background: </strong>During the height of the COVID-19 pandemic (2020-2021), people were urged to minimize movements. Nevertheless, the Netherlands observed a huge increase in new donor registrations in early 2020. It is unclear whether such \"pandemic\" donors are willing to become repeat donors. The aim of this study was to analyze the donation behavior of these \"pandemic\" donors during 2 years after registration.</p><p><strong>Methods: </strong>All donors registered in weeks 11-20 of 2020 were followed for 2 years and their turnout for the new donor screening (NDS), their first-time donation (FTD), their donation(s) in the follow-up period, and their availability at the end of the follow-up period was compared with donors registered in weeks 11-20 of the previous years, 2017-2019.</p><p><strong>Results: </strong>Totally 26,463 donors registered during week 11-20 in 2020; more than double as in the same period in previous years. Their turnout for the NDS (80%) and FTD (60%) was like donors registered in 2017-2019. On the longer term, we saw lower donor availability with a shift in number of whole blood and plasma donations.</p><p><strong>Discussion: </strong>During the first phase of the pandemic, more people registered than usual. Their show rates for the NDS and the FTD were comparable with previous years, suggesting that \"pandemic\" donors show identical behavior as regular donors. On the long term, however, donation behavior differed (lower return rates and shift in donation types). Further research is needed to disentangle impacts of the pandemic especially on the long-term changes as they happened simultaneously with policy and recruitment changes.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":"122-130"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}